DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Moxifloxacin_QT Study in Chinese Healthy Volunteer

Information source: Peking University Third Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: QT Interval Prolongation

Intervention: moxifloxacin (Drug); moxifloxacin-placebo (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Peking University Third Hospital

Official(s) and/or principal investigator(s):
Haiyan Li, MD, Principal Investigator, Affiliation: Peking University Third Hospital

Overall contact:
Jingchuan Guo, MD, Phone: 861082265509, Email: guojingchuan1029@126.com


A single-center, randomized, double-blinded, 2-way crossover, placebo-controlled study to assess the QTc interval after administration of single oral dose of 400mg Moxifloxacin in healthy Chinese subjects.

Clinical Details

Official title: A Single-center, Randomized, Double-blinded, 2-way Crossover, Placebo-controlled Study to Assess the QT/QTc Interval After Administration of Single Oral Dose of 400mg Moxifloxacin in Healthy Chinese Subjects

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: baseline-adjusted, placebo-corrected effect on QTcF (ΔΔQTcF)

Secondary outcome: Heart rate, PR, QRS, QTcB and QTcI


Minimum age: 20 Years. Maximum age: 45 Years. Gender(s): Male.


Inclusion Criteria: 1. Healthy Chinese subjects, male, 20 to 45 years of age included, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening. 2. At Screening, vital signs (systolic and diastolic blood pressure and pulse rate) will be assessed in the sitting position after the subject has rested for 5 minutes. All of vital signs should be within normal ranges:

- Body temperature (Body) between 35. 0-37. 0°C

- 90 ≤ systolic blood pressure <140 mm Hg

- 60≤ diastolic blood pressure < 90 mm Hg

- 50≤ pulse rate ≤ 100

3. Body weight need to be at least 50kg or above, 19kg/m2≤ Body Mass Index(BMI) ≤25kg/m2 4. Be able to communicate well with the investigator, to understand and comply with the requirements of the study. Understand and sign the written informed consent prior to any screening procedures. Exclusion Criteria: 1. History or clinical manifestations of significant metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological, genetic or psychiatric disorders. 2. A past medical history of clinically significant ECG abnormalities or a family history (grandparents, parents and siblings) of long QT syndrome, or QTc interval > 440 ms for male or any abnormal ECG findings at screening. 3. Medical histories of syncope, electrophysiological changes, heart failure, reduced exercise tolerance, cardiomyopathy, pericarditis, myocarditis or other cardiac disorders as determined by the investigator. 4. Current electrolyte abnormalities (specifically hypokalemia) in laboratory examination during the screening that are clinical significant as determined by investigator. 5. Current or recent history (< 30 days prior to Screening) of a clinically significant illness. 6. Use of any prescription drugs, herbal supplements, within 4 weeks prior to initial dosing, and/or over-the-counter (OTC) medication, dietary supplements (vitamins included) within 4 week prior to initial dosing. 7. Positive results of human immunodeficiency virus, Hepatitis B surface antigen or Hepatitis C antibody testing. 8. History of any hypersensitivity or allergic reaction of moxifloxacin or other types fluoroquinolones. 9. Use of tobacco or history of use of tobacco ( > 5 tobacco/week) or nicotine-containing products in the 3 months prior to screening. 10. History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of such abuse as indicated by the laboratory assays conducted during the screening and/or at baseline. 11. Dosing of study drug in any clinical investigation within 3 months prior to initial dosing. 12. Donation or loss of 200 ml or more of blood within 3 months prior to participation, or donation of component blood within 3 months prior to participation.

13. Consumption of alcohol-, caffeine - -containing foods or beverages within 48 hours

preceding study drug administration. 14. Other conditions which investigator deems potential harm to subjects if participate the study.

Locations and Contacts

Jingchuan Guo, MD, Phone: 861082265509, Email: guojingchuan1029@126.com

Peking University Third Hospital Drug Clinical Trial Center, Beijing 100191, China; Recruiting
Haiyan Li, MD, Phone: 861082266226, Email: haianli1027@hotmail.com
Jingchuan Guo, MD, Sub-Investigator
Additional Information

Starting date: July 2012
Last updated: July 30, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017